Accelerant Holdings

ARXNYSEUSD

THESIS ALERT

Email me when the ARX thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$19.87
−$0.04 (−0.20%)Today 1M +0.56%
After hours$19.870.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$19.91
Prior regular-session close from the quote source.
$19.87–$19.90
Regular-session low and high so far today.
571.0K
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$9.18–$19.91
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own ARX if its specialty-insurance marketplace keeps attracting both MGAs and risk capital without turning growth into balance-sheet insurance risk.

ARX price history

Latest price$19.87Today−$0.04 (-0.20%)
ARX +0.35%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Specialty MGAs continue to prefer Accelerant’s marketplace as a route to rated capacity and risk capital rather than building direct carrier or Lloyd’s relationships themselves.StrengtheningMateriality: High

    GAAP annual revenue rose from $344.0 million in FY2023 to $602.6 million in FY2024 and $912.9 million in FY2025. If this holds, Accelerant can keep expanding premium flow; if it breaks, growth becomes dependent on price concessions or riskier programs.

    Watch: Lloyd’s syndicates, traditional specialty carriers, or fronting competitors such as State National offer MGAs cheaper or more flexible capacity directly.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue rose from $344.0 million in FY2023 to $602.6 million in FY2024 and $912.9 million in FY2025.

    Open source ↗
  • Risk-capital providers keep funding Accelerant programs because the platform gives them enough underwriting transparency and control to remain committed through the insurance cycle.HoldingMateriality: High

    GAAP annual operating cash flow was positive in each supplied year: $290.0 million in FY2023, $785.7 million in FY2024, and $445.1 million in FY2025. The marketplace model depends on outside capital staying available; if capital withdraws or reprices sharply, Accelerant’s capacity and economics shrink before revenue does.

    Watch: Reinsurers or alternative-capital partners pull back after catastrophe losses or adverse casualty development in Accelerant-supported programs.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was positive in each supplied year: $290.0 million in FY2023, $785.7 million in FY2024, and.

    Open source ↗
  • Accelerant’s program selection and risk-sharing discipline must keep growth from being purchased with retained losses or adverse development.WeakeningMateriality: Medium

    GAAP annual net income improved from a $64.1 million loss in FY2023 to $22.9 million of profit in FY2024, showing profitability was possible before the FY2025 loss. This is the difference between a valuable marketplace and an insurer taking mispriced tail risk; failure would consume equity and make revenue growth value-destructive.

    Watch: Loss ratios in Accelerant-supported programs deteriorate because of casualty inflation, social inflation, or catastrophe concentration.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual net income improved from a $64.1 million loss in FY2023 to $22.9 million of profit in FY2024, showing.

    Open source ↗
  • Accelerant retains enough equity capital and liquidity to support regulated insurance capacity without being forced into dilutive or restrictive financing.StrengtheningMateriality: Medium

    Stockholders’ equity increased from $304.3 million at FY2024 year-end to $697.7 million at FY2025 year-end. Adequate capital protects the platform’s ability to write and intermediate business; capital stress would hand bargaining power to reinsurers, regulators, and competitors.

    Watch: Regulators or rating agencies require additional capital at Accelerant’s insurance entities after loss development or faster premium growth.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Stockholders’ equity increased from $304.3 million at FY2024 year-end to $697.7 million at FY2025 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Specialty MGAs continue to prefer Accelerant’s marketplace as a route to rated capacity and risk capital rather than building direct carrier or Lloyd’s relationships themselves. If this holds, Accelerant can keep expanding premium flow; if it breaks, growth becomes dependent on price concessions or riskier programs.

Risk-capital providers keep funding Accelerant programs because the platform gives them enough underwriting transparency and control to remain committed through the insurance cycle. The marketplace model depends on outside capital staying available; if capital withdraws or reprices sharply, Accelerant’s capacity and economics shrink before revenue does.

Accelerant’s program selection and risk-sharing discipline must keep growth from being purchased with retained losses or adverse development. This is the difference between a valuable marketplace and an insurer taking mispriced tail risk; failure would consume equity and make revenue growth value-destructive.

Accelerant retains enough equity capital and liquidity to support regulated insurance capacity without being forced into dilutive or restrictive financing. Adequate capital protects the platform’s ability to write and intermediate business; capital stress would hand bargaining power to reinsurers, regulators, and competitors.

All standing thesis claims
Original report summary

its specialty-insurance marketplace keeps attracting both MGAs and risk capital without turning growth into balance-sheet insurance risk.

Evidence assessed Oct 13, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Accelerant Holdings

Where the evidence on Accelerant Holdings disagrees: Mixed on the latest evidence (Oct 13, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.

Bull case: what the evidence supports

  • Specialty MGAs continue to prefer Accelerant’s marketplace as a route to rated capacity and risk capital rather than building direct carrier or Lloyd’s relationships themselves.

    sec.gov ↗

  • Risk-capital providers keep funding Accelerant programs because the platform gives them enough underwriting transparency and control to remain committed through the insurance cycle.

    sec.gov ↗

  • Accelerant retains enough equity capital and liquidity to support regulated insurance capacity without being forced into dilutive or restrictive financing.

    sec.gov ↗

Bear case: what the evidence questions

  • Accelerant’s program selection and risk-sharing discipline must keep growth from being purchased with retained losses or adverse development.

    sec.gov ↗

Thesis-Break Engine

What has broken in Accelerant Holdings’s thesis

Each break OptimistFi flagged on Accelerant Holdings, dated — with what has historically followed the same kind of break across the market, not a forecast for Accelerant Holdings.

peers+14%-15%-1%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -1% path vs comparable companies over six months, inside the middle-half range (+14% to -15%). A base rate, not a forecast.
  • Analyst downgradecondition set before this filing

    Across all companies, this kind of break has happened 12,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Other material event.

    Accelerant Holdings filed an SEC 8-K on 2026-09-23: Other material event. It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Accelerant Holdings filed an SEC 8-K on 2026-08-14: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Accelerant Holdings filed an SEC 8-K on 2026-08-13: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Lloyd’s syndicates, traditional specialty carriers, or fronting competitors such as State National offer MGAs cheaper or more flexible capacity directly.
  • Reinsurers or alternative-capital partners pull back after catastrophe losses or adverse casualty development in Accelerant-supported programs.
  • Loss ratios in Accelerant-supported programs deteriorate because of casualty inflation, social inflation, or catastrophe concentration.
  • Regulators or rating agencies require additional capital at Accelerant’s insurance entities after loss development or faster premium growth.

ARX news

Loading headlines…

Financial statements

ARX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

ARX: quick answers

Which well-known investors own ARX?
1 of the 37 well-known funds tracked here reported ARX shares in their latest 13F filing. By share of the fund's portfolio: Tiger Global Management (Chase Coleman), 0.0%. Fund portfolios

ARX in well-known investors’ portfolios

1 of 37 funds reported ARX shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Chase ColemanTiger Global Management0.00%$879KNo changeQ2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.